Drugs / Medialipide
Medialipide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06595680 | Jan 2025 → Jan 2027 expected | end stage renal failure, hemolytic anemia | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02550860 Comparator | Jan 2015 → Sep 2017 | intestinal disorder | Hospices Civils de Lyon | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Medialipide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02550860 ↗ |
| Known as | Medialipide 20% | “Medialipide® 20% (Braun) is an emulsion of medium chain triglycerides (MCT) (6 to 12 carbons) used in parenteral nutrition.” NCT06595680 ↗ |
| Known as | soybean oil (SO)-based IVFE | “soybean oil (SO)-based IVFE (Medialipide)” NCT02550860 ↗ |
| Modality | Other / unclassified | “soybean oil (SO)-based IVFE” NCT02550860 ↗ |
| Route | Intravenous | “intravenous fat emulsions (IVFE)” NCT02550860 ↗ |